Dynavax Technologies Corporation (DVAX)

Market Cap	1.51B
Revenue (ttm)	232.28M
Net Income (ttm)	-6.39M
Shares Out	130.62M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	60.92
Dividend	n/a
Ex-Dividend Date	n/a

Volume	176,058
Open	11.30
Previous Close	11.34
Day's Range	11.25 - 11.59
52-Week Range	10.06 - 15.15
Beta	1.28
Analysts	Buy
Price Target	25.00 (+115.8%)
Earnings Date	Apr 30, 2024

About DVAX

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, In...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 19, 2004
• Employees: 408
• Stock Exchange: NASDAQ
• Ticker Symbol: DVAX

Analyst Forecast

According to 3 analysts, the average rating for DVAX stock is "Buy." The 12-month stock price forecast is $25.0, which is an increase of 115.80% from the latest price.

Price Target

$25.0

(115.80% upside)

Analyst Consensus: Buy